Pieris Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Pieris Pharmaceuticals's estimated annual revenue is currently $17.4M per year.
- Pieris Pharmaceuticals received $50.6M in venture funding in February 2018. 0
- Pieris Pharmaceuticals's total funding is $194.3M.
Pieris Pharmaceuticals Competitors & Alternatives
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is Pieris Pharmaceuticals?
Pieris Pharmaceuticals (NASDAQ: PIRS) is a clinical stage biotechnology company that discovers and develops Anticalin-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. Pieris is listed on the NASDAQ and trades under the ticker symbol PIRS. Pieris is currently hiring in Boston and Freising, Germany. See here for our full list of job openings and information on applying: https://www.pieris.com/careerskeywords:Biotechnology,Healthcare,Pharmaceuticals
Number of Employees
Employee Growth %
Pieris Pharmaceuticals News
November 2, 2021 Pieris Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update Company To Host an Investor Conference Call on Tuesday, November 2, 2021 at 8:00 AM EDT Dosing completed in part 1a of phase 2a study of PRS-060/AZD1402 Dosing to begin this q ...
November 8, 2021 Pieris Pharmaceuticals and Servier Announce Dosing of First Patient in Phase 1/2 Trial of 4-1BB/PD-L1 Bispecific PRS- 344/S095012 BOSTON, MA and PARIS, FRANCE / ACCESSWIRE / November 8, 2021 /Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company a ...
November 11, 2021 Pieris Pharmaceuticals To Participate In Upcoming Investor Conferences BOSTON, MA / ACCESSWIRE /November 11, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technolog ...
BNP Paribas Arbitrage SA decreased its holdings in Pieris Pharmaceuticals Inc (NASDAQ:PIRS) by 41.3% during the 2nd quarter, according to ...
BOSTON, MA / ACCESSWIRE / September 3, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company ...
About Pieris Pharmaceuticals: Pieris is a clinical-stage biotechnology company that discovers and develops Anticalin protein-based drugs to ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|
Pieris Pharmaceuticals Funding